Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry is a pseudogene related to Bartter syndrome, infantile, with sensorineural deafness (BSND pseudogene). Bartter syndrome is a group of rare renal tubular disorders involving defective salt reabsorption—mutations in the protein-coding BSND gene cause Bartter syndrome type IV, often associated with sensorineural deafness and impaired chloride channel function in the kidney. However, ENSG00000265233 refers to a nonfunctional pseudogene variant, which does not encode a protein or possess biological activity, and is not considered a direct target for drug development[1][5][3]. In summary, ENSG00000265233 is not a valid drug target; it is a pseudogene, not an active molecular entity. For drug targeting or disease mechanism, refer to the protein "Barttin" encoded by the functional BSND gene[1][5][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bartter syndrome, infantile, with sensorineural deafness pseudogene.